ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression.
about
Infections as a cause of autoimmune rheumatic diseasesDiffering specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritisInfectomics and autoinfectomics: a tool to study infectious-induced autoimmunity.An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting.Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.Fingerprinting of anti-citrullinated protein antibodies (ACPA): specificity, isotypes and subclasses.Family history of rheumatoid arthritis: an old concept with new developments.Autoantibodies to human citrullinated fibrinogen and their subfamilies to the α36-50Cit and β60-74Cit fibrin peptides similarly predict radiographic damages: a prospective study in the French ESPOIR cohort of very early arthritides.Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis.The Role of Autoantibodies in Bone Metabolism and Bone Loss.Defining the proteomic landscape of rheumatoid arthritis: progress and prospective clinical applications.The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis.An integrated, peptide-based approach to site-specific protein immobilization for detection of biomolecular interactions.Immunopathogenesis of Rheumatoid Arthritis.The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis
P2860
Q28074204-58FE728E-C983-4316-A37C-FB82420D03ECQ33805043-ED488E8E-EE67-4B3F-8707-5E28EB4E3869Q35584861-2FA7F6F7-5097-4F8D-AB3D-280A7AC77608Q36127049-8B6F76D5-13D3-4CC5-B8E3-ECB2AF4EC502Q36577396-DA845E0B-C77B-4277-BA79-331F807FA4E5Q38388421-78B7BD6E-BD4E-4FD3-AF93-3188B30838EFQ38813384-35766315-8B19-4BD4-857B-F397CC62FC93Q39933222-3BAD8C71-9F10-469A-BA6C-E790CAE73137Q41584831-30C3D2B3-34ED-473E-9522-D3224E5756DCQ47331159-CEE74FF2-C8B0-4A94-95C3-35E30E12B085Q50210105-01960965-C2FB-40C6-8B22-C19F6AFA499CQ50308665-0542A410-007B-4320-B33D-3977E753C771Q51690313-35C19FA8-71E1-4FC0-8CA6-BCAD5FF9EB5CQ54430437-9DD41F5D-FB4B-4208-9BBB-1432EA2E31A3Q55689191-E06B7C0D-ADEE-4DB8-81FA-CEF833D44337Q56967231-718CC555-CA77-4F1B-B06B-17266CE82D33
P2860
ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
ACPA fine-specificity profiles ...... e or with disease progression.
@en
type
label
ACPA fine-specificity profiles ...... e or with disease progression.
@en
prefLabel
ACPA fine-specificity profiles ...... e or with disease progression.
@en
P2093
P2860
P356
P1476
ACPA fine-specificity profiles ...... e or with disease progression.
@en
P2093
Annemiek Willemze
Ger J M Pruijn
Gerard H M Engbers
Jan W Drijfhout
Jeroen J Jansen
Joyce J B C van Beers
Martin Salden
Rene E M Toes
P2860
P2888
P356
10.1186/AR4322
P577
2013-10-01T00:00:00Z
P5875
P6179
1022434111